drugset / Trial / NCT01116271

Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec

NCT01116271

Phase 2 Completed 32 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether treatment with Selumetinib (AZD6244) (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or B-raf mutation will prevent tumor progression and prolong progression free survival.

Timeline

Start
2010-04
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 180 mg/m2 Intravenous
Subject Selumetinib Small molecule 50 mg Oral
Subject Selumetinib Small molecule 75 mg Oral

Indications